Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

The once-weekly anti-TFPI antibody has been cleared by the European Commission for adults and adolescents aged 123 and over with severe haemophilia A or B, without inhibitors, becoming the first ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with ...

▎药明康德出血率降低93%！辉瑞血友病疗法达3期主要与次要终点辉瑞（Pfizer）今日宣布其评估TFPI靶向抗体Hympavzi（marstacimab）用于体内存有抑制物的血友病A或血友病B成人和青少年患者的3期BASIS研究获得积极顶线结果。该研究达到了主要终点和关键的次要出血终点，结果显示每周一次皮下注射Hympavzi在改善关键出血结局方 ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI ...

Pfizer Inc. announced positive topline results from the phase 3 BASIS study (NCT03938792) evaluating Hympavzi (marstacimab) for adults and adolescents living with haemophilia A or B with inhibitors.